319 related articles for article (PubMed ID: 24361757)
1. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin.
Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Rosenzweig M; Lane DA; Lip GY
Am J Med; 2014 Apr; 127(4):329-336.e4. PubMed ID: 24361757
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY
Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361
[TBL] [Abstract][Full Text] [Related]
3. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
Larsen TB; Gorst-Rasmussen A; Rasmussen LH; Skjøth F; Rosenzweig M; Lip GY
Am J Med; 2014 Jul; 127(7):650-656.e5. PubMed ID: 24530792
[TBL] [Abstract][Full Text] [Related]
4. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ
Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
8. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
9. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
[TBL] [Abstract][Full Text] [Related]
10. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
Chevalier J; Giroud M; de Pouvourville G
Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
Ezekowitz MD; Wallentin L; Connolly SJ; Parekh A; Chernick MR; Pogue J; Aikens TH; Yang S; Reilly PA; Lip GY; Yusuf S;
Circulation; 2010 Nov; 122(22):2246-53. PubMed ID: 21147728
[TBL] [Abstract][Full Text] [Related]
12. Myocardial ischemic events in 'real world' patients treated with dabigatran.
Shah R
Am J Med; 2014 Oct; 127(10):e19. PubMed ID: 25311071
[No Abstract] [Full Text] [Related]
13. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
[TBL] [Abstract][Full Text] [Related]
14. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
[TBL] [Abstract][Full Text] [Related]
15. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Bergh M; Marais CA; Miller-Jansön H; Salie F; Stander MP
S Afr Med J; 2013 Feb; 103(4):241-5. PubMed ID: 23547700
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis.
Shurrab M; Morillo CA; Schulman S; Kansal N; Danon A; Newman D; Lashevsky I; Healey JS; Crystal E
Can J Cardiol; 2013 Oct; 29(10):1203-10. PubMed ID: 23993352
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Prescrire Int; 2012 Feb; 21(124):33-6. PubMed ID: 22413715
[TBL] [Abstract][Full Text] [Related]
19. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
20. Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study.
Monz BU; Connolly SJ; Korhonen M; Noack H; Pooley J
Int J Cardiol; 2013 Oct; 168(3):2540-7. PubMed ID: 23664436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
